Don’t miss this free MIMS Learning webinar – Understanding chronic insomnia in adults and its management

Insomnia symptoms are thought to affect 35.0–38.6% of adults and 6.8–14.8% are predicted to have chronic insomnia, yet it remains underdiagnosed and potentially undertreated in primary care.¹

Don’t miss the opportunity to join our expert speaker, Dr Lavan Baskaran, for our live webinar Understanding chronic insomnia and its management. Dr Baskaran will explore the science of sleep and diagnostic approaches for chronic insomnia. He will also uncover the latest on QUVIVIQ™▼ (daridorexant), including its mechanism of action, clinical data, efficacy and safety.

More webinars in Autumn 2025

Further webinars in the series will be taking place in Autumn 2025, please see the registration website for more details.

QUVIVIQ™ (daridorexant) is indicated for the treatment of adult patients with insomnia characterised by symptoms present for at least 3 months and considerable impact on daytime functioning.²

References

1. Hafner M, et al. The societal and economic burden of insomnia in adults: an international study. RAND Corporation, 2023. Accessed June 2025.
2. QUVIVIQ™ Idorsia Pharmaceuticals Ltd, summary of product characteristics.

Click here to view prescribing information and adverse event reporting information

This promotional webinar series has been initiated and funded by Idorsia Pharmaceuticals UK Ltd and is intended for UK healthcare professionals only.
UK-DA-00951 | July 2025